Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 37
Filtrar
1.
J Drugs Dermatol ; 23(4): 209-215, 2024 Apr 01.
Artículo en Inglés | MEDLINE | ID: mdl-38564380

RESUMEN

INTRODUCTION: Chronic exposure to ultraviolet light photoages skin. Retinol, a precursor molecule to retinoic acid that causes less irritation, is available as a nonprescription, cosmetic retinoid and improves collagen production, skin elasticity, and signs of photoaging. Advances in formulation science have allowed the production of stabilized bioactive retinol formulations. This integrated analysis aims to build on previous studies and further examine the comprehensive efficacy and tolerability of topical 0.1% stabilized bioactive retinol. METHODS: This analysis included 6 vehicle-controlled studies of 0.1% stabilized bioactive retinol in women with mild-to-moderate signs of photodamage. Across all studies, the same dermatologist investigator assessed overall photodamage; wrinkles on the forehead, cheeks, and undereye area; crow’s feet wrinkles and fine lines; lack of even skin tone; and brown spots at baseline and weeks 4, 8, and 12 on a numerical scale. Tolerability was also assessed. RESULTS: Participants (retinol, N=237; vehicle, N=234) had a mean (SD) age of 47.4 (6.6) years. Retinol induced greater improvements from baseline in all signs of photoaging vs vehicle as early as week 4 and through 12 weeks of application. Few participants experienced irritation; all events were mild to moderate and transient. The most common signs of irritation were erythema (n=2) and skin scaling/peeling (n=5). CONCLUSIONS: This pooled analysis of 6 vehicle-controlled clinical studies provides new evidence for the efficacy of 0.1% stabilized bioactive retinol in improving signs of photoaging without causing major irritation. Topical 0.1% stabilized bioactive retinol was well tolerated with only a few reported cases of skin irritation. J Drugs Dermatol. 2024;23(4):     doi:10.36849/JDD.8124.


Asunto(s)
Envejecimiento de la Piel , Vitamina A , Femenino , Humanos , Persona de Mediana Edad , Administración Cutánea , Método Doble Ciego , Retinoides , Resultado del Tratamiento , Tretinoina/efectos adversos , Adulto , Ensayos Clínicos Controlados como Asunto
2.
J Am Acad Dermatol ; 90(2): 339-341, 2024 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-37797838

RESUMEN

While the majority of American Academy of Dermatology members have some broad awareness of human trafficking, most are not aware of it in their communities or of the skin signs that could prompt identification of those being exploited, and have requested educational resources to assist patients affected by trafficking. The American Academy of Dermatology Ad Hoc Task Force on Dermatologic Resources for the Intervention and Prevention of Human Trafficking has been working to develop relevant resources, including an online toolkit on the American Academy of Dermatology website: https://www.aad.org/member/clinical-quality/clinical-care/human-trafficking.


Asunto(s)
Dermatología , Trata de Personas , Humanos , Estados Unidos , Comités Consultivos , Academias e Institutos
3.
J Cosmet Dermatol ; 22(11): 2902-2909, 2023 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-37605504

RESUMEN

INTRODUCTION: Acne is a common, complex, multifactorial inflammatory skin disease associated with epidermal barrier dysfunction. Beginning in childhood, acne affects many adolescents and adults. Acne is associated with lower self-esteem, anxiety, and depression and may cause scars and pigmentary sequelae. The review explores the relationships between acne and the skin barrier function and discusses nuances in the prevention, treatment, and maintenance of acne and its impact on the skin barrier. METHODS: The advisors' previous publications addressed prescription and nonprescription pediatric acne treatment and skincare using cleansers, moisturizers, and a practical algorithm for treatment and maintenance, including skincare recommendations for pediatric acne patients and an algorithm for skin of color patients with acne. Before the meeting, literature was culled on the relationship between the skin barrier and acne and current best practices in acne, addressing prescription and nonprescription acne products and skincare as monotherapy, adjunctive, and maintenance treatment. RESULTS: After discussing 13 draft statements, the advisors applied the selected literature and drew from their clinical knowledge and experience, and agreed on five statements. The follicular epithelial barrier is directly involved with changes that occur during both comedogenesis and in stages of inflammation, especially with follicular rupture compromising the barrier's integrity. In acne-affected skin, sebaceous glands are larger, sebum excretion and filaggrin expression higher, and stratum corneum lipids are reduced. Educating patients and clinicians about inflammation's central role in acne and measures to reduce inflammation is essential. Skin irritation and xerosis from acne and treatments lead to poor treatment adherence. A skincare regimen should be included in the acne prevention, treatment, and maintenance care regimen and should be ongoing. Maintenance treatment with topical agents and skincare using gentle ceramide-containing cleansers and moisturizers is a recommended strategy after successfully controlling the disease. CONCLUSIONS: Epidermal barrier dysfunction contributes to acne exacerbation. Using the appropriate treatment and skincare helps to minimize irritation and inflammation, enhance treatment adherence, and improve patient outcomes.

4.
J Cosmet Dermatol ; 22(9): 2391-2398, 2023 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-37403516

RESUMEN

BACKGROUND: The popularity of social media appears to be increasing the acceptance of cosmetic treatments, prompting more consumers to seek cosmetic treatments. As the estimated prevalence of acne vulgaris among adult women may be as high as 54%, acne is commonly observed among patients presenting for cosmetic treatments. Concomitant treatment of acne in the aesthetic patient population will improve overall clinical outcomes. AIMS: The goal of this work was to deliver a high-quality ethical and evidence-based educational program to physicians and adjunctive health care providers to advance patient care. METHODS: This paper is based on a webcam presentation with roundtable discussion by several notable experts in their field. RESULTS: A range of topical medications, injectable products, chemical peels, and energy-based devices are available for treating acne vulgaris. In most instances, these are compatible with rejuvenation procedures in the aesthetic patient. CONCLUSION: The growth of social media is raising awareness of aesthetic procedures and appears to be increasing the number of patients seeking aesthetic treatment. Educating patients about the importance of treating acne vulgaris can improve overall treatment outcomes. In most instances, the presence of acne is not a barrier to aesthetic care.


Asunto(s)
Acné Vulgar , Quimioexfoliación , Adulto , Humanos , Femenino , Acné Vulgar/terapia , Acné Vulgar/complicaciones , Quimioexfoliación/métodos , Dermabrasión , Resultado del Tratamiento , Estética
5.
J Drugs Dermatol ; 21(9): SF3595563-SF35955610, 2022 Sep 01.
Artículo en Inglés | MEDLINE | ID: mdl-36074516

RESUMEN

INTRODUCTION: Rosacea is a chronic condition involving inflammation leading to a diminished skin barrier function in sebaceous gland-rich facial skin. The current algorithm represents part II of a series investigating similar topics associated with preventing, treating, and maintaining rosacea, including ceramides-containing skincare. METHODS: The consensus process consisted of a modified Delphi technique. A previously published review by the US Cutaneous Rosacea Outcomes (USCRO) group on skin barrier deficiency in rosacea and the integration of over-the-counter (OTC) products and skincare recommended for rosacea treatment and maintenance informed the development of the current algorithm. The selected information from the literature searches, coupled with the USCRO group's opinion and experience, was used to develop, discuss, and reach a consensus on an evidence-based clinical treatment and maintenance algorithm focusing on rosacea phenotypes. RESULTS: The algorithm includes foundational measures to be taken by all patients with rosacea and rosacea-prone skin. These measures include education, behavioral modifications, avoidance of triggers and skin irritants, preventative skincare, and sun avoidance and sunscreen use. The algorithm further describes how assessment of skin condition and grading of cutaneous rosacea should take place during treatment and maintenance while the preventative measures continue. CONCLUSIONS: Prescription medications combined with gentle cleansers, moisturizers, and sunscreen support a successful rosacea therapy. J Drugs Dermatol. 2022;21:9(Suppl 1):s3-10.


Asunto(s)
Rosácea , Protectores Solares , Algoritmos , Humanos , Rosácea/diagnóstico , Rosácea/tratamiento farmacológico , Piel , Cuidados de la Piel/métodos , Protectores Solares/uso terapéutico
6.
J Drugs Dermatol ; 20(4): 384-392, 2021 Apr 01.
Artículo en Inglés | MEDLINE | ID: mdl-33852244

RESUMEN

BACKGROUND: Rosacea, an inflammatory skin disease that leads to an impaired skin barrier function commonly involves the face. Symptoms of rosacea can be bothersome and include pain, stinging, burning, itching, and facial flushing. This review explored skin barrier impairment in rosacea and reduced symptomatology when using over the counter (OTC) skincare products. METHODS: Nine dermatologists (the panel) completed a survey on OTC products they recommend for rosacea. The survey results were summarized, presented, and discussed during the online meeting, together with the results of a literature review. The outcome of these discussions, coupled with the panel's expert opinion and experience, is shown in the current review. RESULTS: Addressing barrier dysfunction by use of moisturizer and cleanser formulations that restore skin hydration, normalize skin pH, restore the microbiome, and skin lipids can assist in improving rosacea signs and symptoms. The panel's consensus was that in addition to the use of prescription medications, skincare recommendations are a crucial part of successful rosacea therapy. In addition to occlusives and humectants, barrier restoring ingredients such as ceramides, hyaluronic acid, and niacinamide were considered beneficial. Equally important was the absence of potentially irritating substances. CONCLUSIONS: The use of OTC products can improve rosacea symptomatology and signs. As adjuncts, these products are recommended before and during prescription therapy and as part of a maintenance regimen. J Drugs Dermatol. 20(4):384-392. doi:10.36849/JDD.5861 THIS ARTICLE HAD BEEN MADE AVAILABLE FREE OF CHARGE. PLEASE SCROLL DOWN TO ACCESS THE FULL fTEXT OF THIS ARTICLE WITHOUT LOGGING IN. NO PURCHASE NECESSARY. PLEASE CONTACT THE PUBLISHER WITH ANY QUESTIONS.


Asunto(s)
Fármacos Dermatológicos/administración & dosificación , Medicamentos sin Prescripción/administración & dosificación , Medicamentos bajo Prescripción/administración & dosificación , Rosácea/terapia , Cuidados de la Piel/métodos , Administración Cutánea , Terapia Combinada/métodos , Terapia Combinada/normas , Consenso , Dermatología/métodos , Dermatología/normas , Humanos , Microbiota/efectos de los fármacos , Guías de Práctica Clínica como Asunto , Rosácea/microbiología , Rosácea/patología , Índice de Severidad de la Enfermedad , Piel/efectos de los fármacos , Piel/microbiología , Piel/patología , Cuidados de la Piel/normas , Resultado del Tratamiento , Pérdida Insensible de Agua/efectos de los fármacos
9.
J Drugs Dermatol ; 17(10): 1070-1076, 2018 Oct 01.
Artículo en Inglés | MEDLINE | ID: mdl-30365587

RESUMEN

Atopic dermatitis (AD) is well-recognized as a very common chronic and relapsing pruritic skin disorder affecting both children and adults worldwide. The adverse effects on the quality of life of affected individuals and their families is well-established. The pathophysiology of AD is complex, leading to interindividual variations in clinical presentation and severity. The chronicity of AD, characterized by periods of exacerbation and remission, supports a strong need to develop measures that can effectively and safely prolong remissions between flares of the disease. This article provides an overview of AD including prevalence, severity, and disease course/progression, succinct summaries of pathophysiology and medical management, and discussion of epidermal barrier dysfunction and skin microbiome shifting associated with AD. Additional emphasis is placed on adjunctive topical skin barrier approaches that may prolong disease-free remissions. Results from a panel of dermatologists queried about adjunctive approaches to AD, using a modified-Delphi approach, are also discussed. J Drugs Dermatol. 2018;17(10):1070-1076.

THIS ARTICLE HAD BEEN MADE AVAILABLE FREE OF CHARGE.

PLEASE SCROLL DOWN TO ACCESS THE FULL TEXT OF THIS ARTICLE WITHOUT LOGGING IN.

NO PURCHASE NECESSARY.

PLEASE CONTACT THE PUBLISHER WITH ANY QUESTIONS.

.


Asunto(s)
Dermatitis Atópica/epidemiología , Fármacos Dermatológicos/uso terapéutico , Administración Cutánea , Adolescente , Adulto , Quimioterapia Adyuvante , Niño , Preescolar , Dermatitis Atópica/tratamiento farmacológico , Dermatitis Atópica/patología , Dermatitis Atópica/fisiopatología , Fármacos Dermatológicos/administración & dosificación , Progresión de la Enfermedad , Supervivencia sin Enfermedad , Femenino , Humanos , Lactante , Masculino , Prevalencia , Adulto Joven
10.
J Drugs Dermatol ; 17(1): 78-82, 2018 Jan 01.
Artículo en Inglés | MEDLINE | ID: mdl-29320591

RESUMEN

Hand dermatitis is estimated to affect greater than 15% of the general population. Childhood eczema, frequent hand washing, and occupational exposure to chemicals are predisposing factors. Hand dermatitis treatment involves both prevention of outbreaks and treatment of active disease. Moisturizers are essential to protect the skin from the environment, enhance hydration, and repair the skin barrier. They have been shown in large studies to prevent occupational related breakouts. Natural oils are commonly used in moisturizers for their moisturizing and emollient properties. Sweet almond oil is an oil that contains high levels of fatty acids and has been used for centuries to treat skin diseases such as eczema and psoriasis. In this study, a moisturizer with 7% sweet almond oil and 2% colloidal oatmeal was found to be both safe and effective in treating patients with moderate to severe hand dermatitis.

J Drugs Dermatol. 2018;17(1):78-82.

.


Asunto(s)
Dermatitis Profesional/tratamiento farmacológico , Eccema/tratamiento farmacológico , Dermatosis de la Mano/tratamiento farmacológico , Aceites de Plantas/uso terapéutico , Crema para la Piel/uso terapéutico , Adulto , Femenino , Humanos , Masculino , Persona de Mediana Edad , Medicamentos sin Prescripción , Satisfacción del Paciente , Aceites de Plantas/análisis , Crema para la Piel/química , Fenómenos Fisiológicos de la Piel/efectos de los fármacos , Adulto Joven
11.
J Drugs Dermatol ; 15(7): 863-8, 2016 Jul 01.
Artículo en Inglés | MEDLINE | ID: mdl-27391637

RESUMEN

Consumers are increasingly interested in over-the-counter skin care products that can improve the appearance of photodamaged and aging skin. This 10-week, open-label, single- center study enrolled 25 subjects with mild to moderate hyperpigmentation and other clinical stigmata of cutaneous aging including fine lines, sallowness, lack of clarity, and wrinkling. Their mean age was 53.4±7.7 years. The test product contained retinol 0.5% in combination with niacinamide 4.4%, resveratrol 1%, and hexylresorcinol 1.1% in a moisturizing base. Subjects were provided a skin care regimen including a cleanser, hydrating serum, moisturizer, and an SPF 30 sunscreen for daily use. The test product was applied only at night.

The use of this skin brightening/anti-aging cosmeceutical was found to provide statistically significant improvements in all efficacy endpoints by study end. Fine lines, radiance, and smoothness were significantly improved as early as week 2 (P<.001). By week 4, hyperpigmentation, overall skin clarity, evenness of skin tone, and wrinkles showed statistically significant improvement compared to baseline. Mild retinoid dermatitis including flaking and redness occurred early in the study as reflected by tolerability scores. By week 10, subjects reported no stinging, itching, dryness, or tingling.

The results of this open-label clinical study suggest that a topical cream containing retinol 0.5% in combination with niacinamide, resveratrol, and hexylresorcinol is efficacious and tolerable for skin brightening/anti-aging when used with a complementary skin care regimen including SPF 30 sun protection.

J Drugs Dermatol. 2016;15(7):863-868.


Asunto(s)
Cosmecéuticos/administración & dosificación , Hexilresorcinol/administración & dosificación , Niacinamida/administración & dosificación , Envejecimiento de la Piel/efectos de los fármacos , Estilbenos/administración & dosificación , Vitamina A/administración & dosificación , Administración Cutánea , Cosmecéuticos/efectos adversos , Combinación de Medicamentos , Erupciones por Medicamentos/diagnóstico , Erupciones por Medicamentos/etiología , Femenino , Hexilresorcinol/efectos adversos , Humanos , Persona de Mediana Edad , Niacinamida/efectos adversos , Resveratrol , Envejecimiento de la Piel/patología , Cuidados de la Piel/métodos , Pigmentación de la Piel/efectos de los fármacos , Estilbenos/efectos adversos , Encuestas y Cuestionarios , Resultado del Tratamiento , Vitamina A/efectos adversos
12.
J Am Acad Dermatol ; 74(5): 945-73.e33, 2016 May.
Artículo en Inglés | MEDLINE | ID: mdl-26897386

RESUMEN

Acne is one of the most common disorders treated by dermatologists and other health care providers. While it most often affects adolescents, it is not uncommon in adults and can also be seen in children. This evidence-based guideline addresses important clinical questions that arise in its management. Issues from grading of acne to the topical and systemic management of the disease are reviewed. Suggestions on use are provided based on available evidence.


Asunto(s)
Acné Vulgar/diagnóstico , Acné Vulgar/tratamiento farmacológico , Antibacterianos/uso terapéutico , Fármacos Dermatológicos/uso terapéutico , Guías de Práctica Clínica como Asunto , Administración Oral , Administración Tópica , Adolescente , Adulto , Medicina Basada en la Evidencia , Femenino , Estudios de Seguimiento , Humanos , Isotretinoína/uso terapéutico , Masculino , Recurrencia , Medición de Riesgo , Resultado del Tratamiento , Adulto Joven
14.
J Drugs Dermatol ; 14(10): 1119-25, 2015 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-26461823

RESUMEN

Seborrheic keratosis (SK) is among the most common cutaneous lesions, affecting some 83 million Americans. Biologically benign, SK lesions do not require removal for medical reasons unless histologic confirmation of the clinical diagnosis is required or the lesions are traumatized and/or become symptomatic. These macular or popular pigmented lesions are often of cosmetic concern to patients. In addition, their natural history of gradually increasing in size, thickness, and/or pigmentation often serves as the impetus compelling patients to present to a dermatologist for evaluation and skin cancer screening; SK is diagnosed and managed primarily by dermatologists. Data regarding SK prevalence and management from a survey of 594 practicing, board-certified dermatologists are summarized herein: Dermatologists report they diagnose an average of 155 patients per month with SK. Among SK patients presenting to dermatologists, 33% have more than 15 SK lesions and 67% have 15 or fewer SK lesions. On average, dermatologists treat 43% of their SK patients to remove lesions. Cryosurgery is the most common removal method. Other commonly employed removal methods include shave excision, electrodessication, curettage or a combination of these. While these procedures can be used to remove SK lesions effectively, each has potential drawbacks and careful patient selection is required to optimize cosmetic results particularly in skin of color patients and patients with thick or numerous lesions. While there is great interest from both patients and providers in a topical non-invasive treatment for SK, no effective topical therapeutic agent has been developed, and this remains an area of unmet need.


Asunto(s)
Dermatología/métodos , Queratosis Seborreica/patología , Selección de Paciente , Criocirugía/métodos , Legrado/métodos , Humanos , Queratosis Seborreica/diagnóstico , Queratosis Seborreica/epidemiología , Prevalencia , Estados Unidos/epidemiología
15.
Cutis ; 93(3): 134-8, 2014 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-24738094

RESUMEN

The last article in this 5-part series provides a final overview of consensus recommendations from the American Acne & Rosacea Society (AARS) on the management of the common presentations of cutaneous rosacea. Optimal management of rosacea requires careful assessment of the patient's clinical features with integration of therapies that adequately treat the presenting signs and symptoms. The treatment consensus recommendations from the AARS are based on 2 major common clinical presentations of rosacea: (1) centrofacial erythema with papulopustular lesions, and (2) centrofacial erythema without papulopustular lesions. The recommendations provided here serve to guide clinicians in their clinical practice.


Asunto(s)
Agonistas de Receptores Adrenérgicos alfa 2/uso terapéutico , Antiinfecciosos/uso terapéutico , Fármacos Dermatológicos/uso terapéutico , Eritema/tratamiento farmacológico , Rosácea/tratamiento farmacológico , Administración Cutánea , Administración Oral , Tartrato de Brimonidina , Consenso , Ácidos Dicarboxílicos/uso terapéutico , Doxiciclina/uso terapéutico , Eritema/etiología , Humanos , Metronidazol/uso terapéutico , Quinoxalinas/uso terapéutico , Rosácea/complicaciones , Índice de Severidad de la Enfermedad , Sociedades Médicas
16.
Cutis ; 93(2): 71-6, 2014 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-24605343

RESUMEN

The fourth article in this 5-part series reviews physical modalities and devices used to treat cutaneous rosacea based on consensus recommendations from the American Acne & Rosacea Society (AARS) on the management of the common presentations of cutaneous rosacea. The major therapeutic uses of physical modalities and devices, especially laser and light-based systems, are for treatment of telangiectases and persistent facial erythema (background erythema). Phymas, especially rhinophyma, also are treated with physical modalities such as ablative lasers or surgical devices (eg, electrosurgical loop). Appropriately selected and properly used lasers and intense pulsed light (IPL) devices can successfully address specific clinical manifestations of rosacea that exhibit limited or no response to available medical therapies, such as telangiectases and background centrofacial erythema. Rosacea-associated symptoms also may improve. In most cases, treatment will need to be repeated intermittently to sustain improvement.


Asunto(s)
Eritema/terapia , Tratamiento de Luz Pulsada Intensa/métodos , Terapia por Láser/métodos , Láseres de Colorantes/uso terapéutico , Terapia por Luz de Baja Intensidad/métodos , Rosácea/terapia , Telangiectasia/terapia , Eritema/etiología , Humanos , Rosácea/complicaciones , Sociedades Médicas , Telangiectasia/etiología
17.
J Drugs Dermatol ; 13(3): 326-31, 2014 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-24595579

RESUMEN

Rosacea is a condition most commonly characterized by central facial erythema and pupulopustules. There are highly effective drugs, both oral and topical, for papulopustular disease. At the present time, consistently effective pharmacologic therapy for erythematotelangiectatic rosacea is lacking. Patients whose papulopustular disease has been adequately treated are often still bothered by central facial erythema for which there is no adequate treatment short of laser and light. We present a study utilizing a novel topical composition evaluated for its ability to reduce background erythema remaining after adequate care of papulopustular disease. Patient, investigator and photographic evidence of erythema reduction was seen in 24/25 patients in this 8-week study.


Asunto(s)
Fármacos Dermatológicos/uso terapéutico , Eritema/tratamiento farmacológico , Rosácea/tratamiento farmacológico , Administración Cutánea , Fármacos Dermatológicos/administración & dosificación , Eritema/etiología , Femenino , Humanos , Masculino , Rosácea/patología , Resultado del Tratamiento
18.
Cutis ; 93(1): 18-28, 2014 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-24505581

RESUMEN

The third article in this 5-part series reviews systemic therapies used to treat cutaneous rosacea based on consensus recommendations from the American Acne & Rosacea Society (AARS) on the management of the common presentations of cutaneous rosacea. The consensus recommendations are based on current understanding of research that describes pathophysiologic mechanisms that appear to be operative in rosacea, correlation of these underlying pathophysiologic mechanisms with specific clinical manifestations of rosacea, and outcomes from clinical trials that evaluate therapies for rosacea both as monotherapy and in combination with other agents. Systemic agents used for treatment of rosacea have been administered as oral formulations (ie, tablets, capsules). The only oral agent for rosacea approved by the US Food and Drug Administration (FDA) is a modified-release doxycycline 40-mg capsule. Other non-FDA-approved oral agents also are discussed including other tetracyclines, macrolides, metronidazole, and isotretinoin.


Asunto(s)
Fármacos Dermatológicos/uso terapéutico , Rosácea/tratamiento farmacológico , Administración Oral , Consenso , Fármacos Dermatológicos/administración & dosificación , Aprobación de Drogas , Humanos , Rosácea/fisiopatología , Sociedades Médicas , Estados Unidos , United States Food and Drug Administration
19.
Dermatol Clin ; 32(1): 13-21, 2014 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-24267418

RESUMEN

The aging process is unavoidable and often augmented by extrinsic forces, such as ultraviolet radiation. The increasing middle-aged population is leading to the production of many new cosmetic products promising improvement of the various signs of aging, termed cosmeceuticals. Within this booming industry, several different types exist. This article focuses on updates in those involving peptides, growth factors, cytokines, and stem cells.


Asunto(s)
Cosméticos/administración & dosificación , Péptidos y Proteínas de Señalización Intercelular/administración & dosificación , Péptidos/farmacología , Envejecimiento de la Piel/efectos de los fármacos , Administración Tópica , Citocinas/administración & dosificación , Citocinas/farmacología , Esquema de Medicación , Humanos , Péptidos y Proteínas de Señalización Intercelular/uso terapéutico , Persona de Mediana Edad , Péptidos/administración & dosificación , Células Madre
20.
Cutis ; 92(5): 234-40, 2013 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-24343208

RESUMEN

Rosacea is a common clinical diagnosis that encompasses a variety of presentations, predominantly involving the centrofacial skin. Reported to present most commonly in adults of Northern European heritage with fair skin, rosacea can affect males and females of all ethnicities and skin types. Pathophysiologic mechanisms that appear to correlate with the manifestation of rosacea have been the focus of multiple research studies, with outcomes providing a better understanding of why some individuals are affected and how their visible signs and symptoms develop. A better appreciation of the pathophysiologic mechanisms and inflammatory pathways of rosacea has allowed therapeutic strategies to be optimally incorporated. Part 1 of this 5-part series discusses the rosacea disease state with an emphasis on clinical correlation, reviews adjunctive skin care for cutaneous rosacea, and provides management caveats.


Asunto(s)
Dermatosis Facial/diagnóstico , Dermatosis Facial/terapia , Rosácea/diagnóstico , Rosácea/terapia , Cuidados de la Piel , Consenso , Femenino , Humanos , Masculino , Rosácea/clasificación , Protectores Solares/uso terapéutico
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA